Cited by 257Microtubule and mitosis dynamicsUbiquitin and proteasome pathwaysCancer-related Molecular Pathways

Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C

Open access
Sackton, Katharine L., Dimova, Nevena, Zeng, Xing, Tian, Wei, Zhang, Mengmeng, Sackton, Timothy B., Meaders, Johnathan, Pfaff, Kathleen L. +4 more·2014·Nature

Abstract

Protein machines are multi-subunit protein complexes that orchestrate highly regulated biochemical tasks. An example is the anaphase-promoting complex/cyclosome (APC/C), a 13-subunit ubiquitin ligase that initiates the metaphase-anaphase transition and mitotic exit by targeting proteins such as securin and cyclin B1 for ubiquitin-dependent destruction by the proteasome. Because blocking mitotic exit is an effective approach for inducing tumour cell death, the APC/C represents a potential novel target for cancer therapy. APC/C activation in mitosis requires binding of Cdc20 (ref. 5), which forms a co-receptor with the APC/C to recognize substrates containing a destruction box (D-box). Here we demonstrate that we can synergistically inhibit APC/C-dependent proteolysis and mitotic exit by simultaneously disrupting two protein-protein interactions within the APC/C-Cdc20-substrate ternary complex. We identify a small molecule, called apcin (APC inhibitor), which binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates. Analysis of the crystal structure of the apcin-Cdc20 complex suggests that apcin occupies the D-box-binding pocket on the side face of the WD40-domain. The ability of apcin to block mitotic exit is synergistically amplified by co-addition of tosyl-l-arginine methyl ester, a small molecule that blocks the APC/C-Cdc20 interaction. This work suggests that simultaneous disruption of multiple, weak protein-protein interactions is an effective approach for inactivating a protein machine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature13660

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The substrate-binding domain of CDC20 is chemically tractable.

    “suggesting that this domain is chemically tractable 62 .”

    From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]

  • A weak small-molecule ligand that binds the substrate-binding domain of CDC20 was previously reported.

    “Additionally, a weak small-molecule ligand that binds the substrate-binding domain of CDC20 was previously reported, suggesting that this domain is chemically tractable 62 .”

    From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]

  • Substrate competitors with CDC20 block mitotic exit and induce tumour cell death.

    “Substrate competitors with CDC20 block mitotic exit and induce tumour cell death 62 ,”

    From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]

  • Apcin binds at the CDC20 site and inhibits ubiquitylation of D-box-containing substrates.

    “apcin, a small molecule that binds at the same CDC20 site, inhibits the ubiquitylation of D-box-containing substrates 62 .”

    From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]

  • Apcin binds CDC20 with low-micromolar affinity and occupies the D-box binding site.

    “apcin, that binds CDC20 with low-micromolar affinity occupies the D-box binding site of the ligase”

    From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 41 · Cited by 257

Authors
Sackton, K. L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T. B., Meaders, J., Pfaff, K. L., Sigoillot, F., Yu, H., Luo, X., & King, R. W.
Affiliations
  • Harvard University (US)
  • Howard Hughes Medical Institute (US)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
King, Randall W.
Venue
Nature
Published
2014-08-24
Volume
514
Issue
7524
Pages
646-649
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W1988852424
Cited by
257
References
41
Citations by year
2026: 14 · 2025: 22 · 2024: 19 · 2023: 14 · 2022: 21 · 2021: 31 · 2020: 36 · 2019: 24 · 2018: 15 · 2017: 22 · 2016: 25 · 2015: 12 · 2014: 2
FWCI
10.30
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Institute of General Medical Sciences (R56GM066492, R01GM066492, GM085004, GM066492, R01GM085004)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
anaphase-promoting complex, CDC20, mitotic exit, protein-protein interaction inhibitors, ubiquitin ligase, D-box, WD40 domain, proteasome, securin, cyclin B1, synergistic inhibition, cancer therapy, ubiquitination
MeSH terms
Binding Sites, Carbamates, Diamines, Drug Synergism, Mitosis, Protein Binding, Tosylarginine Methyl Ester, Cell Death, Crystallography, X-Ray, Ubiquitination, Proteolysis, Anaphase-Promoting Complex-Cyclosome, Cdc20 Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review